The Sunday Ticket class action returned to court, for oral argument on the appeal of the trial judge’s decision to throw out a $4.7 billion antitrust verdict entered by a jury against the league.

For both the fourth quarter and full year 2025, the increases in R&D expenses were primarily due to higher clinical trial and manufacturing costs associated with the development of soquelitinib as ...